Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.25
NPSP's Cash to Debt is ranked higher than
58% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. NPSP: 1.25 )
NPSP' s 10-Year Cash to Debt Range
Min: 0.22   Max: 96771
Current: 1.25

0.22
96771
Equity to Asset 0.38
NPSP's Equity to Asset is ranked higher than
56% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NPSP: 0.38 )
NPSP' s 10-Year Equity to Asset Range
Min: -1.62   Max: 0.99
Current: 0.38

-1.62
0.99
F-Score: 3
Z-Score: 6.68
M-Score: -2.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -0.96
NPSP's Operating margin (%) is ranked higher than
80% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. NPSP: -0.96 )
NPSP' s 10-Year Operating margin (%) Range
Min: -4401.9   Max: 47.29
Current: -0.96

-4401.9
47.29
Net-margin (%) -8.68
NPSP's Net-margin (%) is ranked higher than
78% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. NPSP: -8.68 )
NPSP' s 10-Year Net-margin (%) Range
Min: -4031.2   Max: 30.05
Current: -8.68

-4031.2
30.05
ROE (%) -12.87
NPSP's ROE (%) is ranked higher than
75% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. NPSP: -12.87 )
NPSP' s 10-Year ROE (%) Range
Min: -151.08   Max: 8.73
Current: -12.87

-151.08
8.73
ROA (%) -4.62
NPSP's ROA (%) is ranked higher than
79% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. NPSP: -4.62 )
NPSP' s 10-Year ROA (%) Range
Min: -54.92   Max: 8.45
Current: -4.62

-54.92
8.45
ROC (Joel Greenblatt) (%) -3.02
NPSP's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. NPSP: -3.02 )
NPSP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3352.81   Max: 10668.28
Current: -3.02

-3352.81
10668.28
Revenue Growth (%) 1.30
NPSP's Revenue Growth (%) is ranked higher than
77% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. NPSP: 1.30 )
NPSP' s 10-Year Revenue Growth (%) Range
Min: -47.8   Max: 90.4
Current: 1.3

-47.8
90.4
EBITDA Growth (%) -65.80
NPSP's EBITDA Growth (%) is ranked higher than
50% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. NPSP: -65.80 )
NPSP' s 10-Year EBITDA Growth (%) Range
Min: -75.6   Max: 87.7
Current: -65.8

-75.6
87.7
EPS Growth (%) -36.20
NPSP's EPS Growth (%) is ranked higher than
60% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. NPSP: -36.20 )
NPSP' s 10-Year EPS Growth (%) Range
Min: -86.9   Max: 278
Current: -36.2

-86.9
278
» NPSP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

NPSP Guru Trades in Q2 2013

Jim Simons 204,900 sh (New)
RS Investment Management 1,970,092 sh (+67.04%)
Steven Cohen 201,900 sh (+0.6%)
Columbia Wanger 5,207,000 sh (unchged)
Louis Moore Bacon Sold Out
Pioneer Investments 658,318 sh (-36.1%)
» More
Q3 2013

NPSP Guru Trades in Q3 2013

Jim Simons Sold Out
Columbia Wanger 4,445,000 sh (-14.63%)
RS Investment Management 1,439,745 sh (-26.92%)
Pioneer Investments 448,811 sh (-31.82%)
Steven Cohen 105,901 sh (-47.55%)
» More
Q4 2013

NPSP Guru Trades in Q4 2013

Steven Cohen 123,245 sh (+16.38%)
RS Investment Management 1,536,945 sh (+6.75%)
Pioneer Investments 369,214 sh (-17.74%)
Columbia Wanger 3,635,300 sh (-18.22%)
» More
Q1 2014

NPSP Guru Trades in Q1 2014

Jim Simons 23,500 sh (New)
John Burbank 6,756 sh (New)
Mariko Gordon 14,828 sh (New)
Steven Cohen 260,800 sh (+111.61%)
RS Investment Management 1,529,445 sh (-0.49%)
Columbia Wanger 2,771,000 sh (-23.78%)
Pioneer Investments 274,256 sh (-25.72%)
» More
» Details

Insider Trades

Latest Guru Trades with NPSP

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mariko Gordon 2014-03-31 New Buy0.02%$27.55 - $39.06 $ 29.72-14%14828
John Burbank 2014-03-31 New Buy0.01%$27.55 - $39.06 $ 29.72-14%6756
George Soros 2011-12-31 Sold Out 0.06%$4.97 - $7.76 $ 29.72380%0
George Soros 2011-09-30 Add 98.31%0.03%$6.11 - $10.18 $ 29.72272%545349
George Soros 2011-06-30 Reduce -64.44%0.07%$8.84 - $10.45 $ 29.72212%275000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about NPS Pharmaceuticals Inc

Weekly CFO Sells Highlight: WRES, NPSP, MKTO, GRPN, RXN
According to GuruFocus Insider Data, the largest CFO sells during the past week were: Warren Resources Inc, NPS Pharmaceuticals Inc, Marketo Inc, Groupon Inc, and Rexnord Corp. Read more...

Ratios

vs
industry
vs
history
P/B 29.20
NPSP's P/B is ranked higher than
57% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. NPSP: 29.20 )
NPSP' s 10-Year P/B Range
Min: 5.86   Max: 38.23
Current: 29.2

5.86
38.23
P/S 17.20
NPSP's P/S is ranked higher than
74% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. NPSP: 17.20 )
NPSP' s 10-Year P/S Range
Min: 1.6   Max: 156.29
Current: 17.2

1.6
156.29
EV-to-EBIT 34747.89
NPSP's EV-to-EBIT is ranked lower than
54% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NPSP: 34747.89 )
NPSP' s 10-Year EV-to-EBIT Range
Min: 4.5   Max: 40360.9
Current: 34747.89

4.5
40360.9
Current Ratio 4.87
NPSP's Current Ratio is ranked higher than
76% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. NPSP: 4.87 )
NPSP' s 10-Year Current Ratio Range
Min: 0.52   Max: 96.48
Current: 4.87

0.52
96.48
Quick Ratio 4.23
NPSP's Quick Ratio is ranked higher than
75% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. NPSP: 4.23 )
NPSP' s 10-Year Quick Ratio Range
Min: 0.52   Max: 96.48
Current: 4.23

0.52
96.48

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2972.00
NPSP's Price/Net Cash is ranked higher than
72% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. NPSP: 2972.00 )
NPSP' s 10-Year Price/Net Cash Range
Min: 1.76   Max: 2993
Current: 2972

1.76
2993
Price/Net Current Asset Value 74.30
NPSP's Price/Net Current Asset Value is ranked higher than
73% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. NPSP: 74.30 )
NPSP' s 10-Year Price/Net Current Asset Value Range
Min: 1.76   Max: 262.5
Current: 74.3

1.76
262.5
Price/Tangible Book 39.60
NPSP's Price/Tangible Book is ranked higher than
61% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. NPSP: 39.60 )
NPSP' s 10-Year Price/Tangible Book Range
Min: 1.6   Max: 51.31
Current: 39.6

1.6
51.31
Price/Median PS Value 2.90
NPSP's Price/Median PS Value is ranked higher than
68% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. NPSP: 2.90 )
NPSP' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 64.42
Current: 2.9

0.31
64.42
Forward Rate of Return (Yacktman) -0.97
NPSP's Forward Rate of Return (Yacktman) is ranked higher than
86% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. NPSP: -0.97 )
NPSP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -122.6   Max: -0.7
Current: -0.97

-122.6
-0.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NPM.Germany
NPS Pharmaceuticals, Inc is a biopharmaceutical company, which is focused on the development of new treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs. The Company's clinical programs involve two proprietary therapeutic proteins to restore or replace biological function: GATTEX(tm) (teduglutide) and Natpara (parathyroid hormone 1-84 [rDNA origin] injection). GATTEX is its analog of GLP-2, a protein involved in the regeneration and repair of the intestinal lining, and is in Phase 3 clinical development for parenteral dependent (PN) short bowel syndrome (SBS). SBS is a highly disabling condition that results from surgical resection, congenital defect or disease-associated loss of absorption and the subsequent inability to maintain fluid, electrolyte, and nutrient balances on a conventional diet. Natpara is the Company's recombinant full-length human parathyroid hormone (PTH 1-84) that is in Phase 3 clinical development for hypoparathyroidism, a rare condition in which the body does not maintain normal calcium levels in the blood due to insufficient levels of parathyroid hormone. The Company is currently advancing registration studies for GATTEX and Natpara. The Company has collaborations or royalty agreements with a number of pharmaceutical companies. 'NPS, 'NPS Pharmaceuticals', 'GATTEX', and 'PREOS' are the Company's trademarks. The Company has competitors in both the U.S. and internationally including multi-national pharmaceutical companies, chemical companies, biotech companies, universities and other research organizations. Many of its competitors have drug products that have already been approved or are in development, and operate large, well-funded research and development programs in these fields.
» More Articles for NPSP

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: WRES, NPSP, MKTO, GRPN, RXN Sep 29 2013 
Weekly CFO Sells Highlight: KO, KKD, PIR, NPSP, ACAD Apr 16 2013 
NPS Pharmaceuticals Reports Second Quarter 2009 Financial Results; Two Phase 3 Registration Programs Aug 06 2009 
NPS Pharmaceuticals to Report Second Quarter Financial Results on August 6, 2009 Aug 03 2009 
NPS Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2009 
George Soros Buys Partner Communications Co. Ltd, CR Bard Inc., Valley Forge Scientific Corp., Sells Aug 15 2006 

More From Other Websites
Nasdaq stocks posting largest percentage increases Jul 22 2014
NPS Pharmaceuticals: The Small Bio-Tech You Should Not Be Ignoring With 30% Upside Jul 21 2014
Despite Selloff, Traders Remain Positive on AbbVie Deal Jul 08 2014
NPS Pharmaceuticals' Gattex Gets Updated Label Jul 01 2014
FDA Approves Updated Labeling for Gattex® (Teduglutide [rDNA origin]) for Injection to Include... Jun 30 2014
Shire shares rise on hopes of higher AbbVie offer Jun 30 2014
PRESS DIGEST-Sunday British Business-June 29 Jun 29 2014
Biotechnology Equities Movers and Shakers -- Research on ZIOPHARM Oncology, Clovis Oncology,... Jun 27 2014
Valeant Goes For Allergan; Analyst Touts Shire Option Jun 18 2014
NPS Pharma's Natpara Likely to be Reviewed in September Jun 11 2014
Shire's Potential Offer For NPS Pharma Is Too Low Jun 11 2014
NPS PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jun 10 2014
NPS Pharma Reports Change in Tentative Date of FDA Advisory Committee Review of Natpara® BLA to... Jun 10 2014
NPS Pharma to Present at Goldman Sachs Global Healthcare Conference Jun 03 2014
NPS Says It Hasn’t Heard From Shire About Potential Deal Jun 02 2014
NPS PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure Jun 02 2014
Mid-Afternoon Market Update; ISM Revised Twice, CONN Maintains Gains On Earnings Report Jun 02 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide